NFE2L1 and Miyoshi myopathy: The TCF11/Nrf1 pathway is an attractive therapeutic target for MM, because its activation upon proteasome impairment results in the synthesis of new proteasome subunits, thus augmenting the effect of proteasome inhibitors [5,11].